In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder-Reference-Cited by-同舟云学术

In Vivo Occupancy of Dopamine D3 Receptors by Antagonists Produces Neurochemical and Behavioral Effects of Potential Relevance to Attention-Deficit–Hyperactivity Disorder

Published:2012-11-29 Issue:2 Volume:344 Page:501-510
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Barth V.,Need A. B.,Tzavara E. T.,Giros B.,Overshiner C.,Gleason S. D.,Wade M.,Johansson A. M.,Perry K.,Nomikos G. G.,Witkin J. M.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference45 articles.

1. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer

2. DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents

3. (+)-UH 232, a partial agonist of the D3 dopamine receptors, attenuates cognitive effects of angiotensin IV and des-Phe6-angiotensin IV in rats

4. IV. Measurement of acetylcholine and choline in brain by HPLC with electrochemical detection

5. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: Dopamine D2, serotonin 2A and NK-1 receptors as examples

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dopamine Transporter Deficient Rodents: Perspectives and Limitations for Neuroscience;Biomolecules;2023-05-09

2. REBOKSETİN’İN DİYABETİK SIÇANLARDA BOZULMUŞ DAVRANIŞ PARAMETRELERİ ÜZERİNDEKİ YARARLI ETKİLERİ;Ankara Universitesi Eczacilik Fakultesi Dergisi;2022-11-21

3. Mechanisms Underlying Dopaminergic Regulation of Nicotine-Induced Kinetic Tremor;Frontiers in Pharmacology;2022-06-16

4. Cariprazine in the Treatment of Psychosis;NeuroPsychopharmacotherapy;2022

5. Cariprazine in the Treatment of Psychosis;NeuroPsychopharmacotherapy;2022